Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Realheart Appoints New Interim Chief Financial Officer

Scandinavian Real Heart
Download the release

Västerås, August 9, 2024 – Scandinavian Real Heart AB (publ) announces today that Jimmy Nybom will succeed Andreas Hultdin as interim Chief Financial Officer (CFO) during the ongoing recruitment process of a permanent CFO. Jimmy Nybom will start his assignment on September 6.

Jimmy Nybom holds a Master of Science (MSc) in Business Administration and Economics, with a specialization in Accounting and Finance, from Umeå University. Mr Nybom has previous experience as interim CFO and board member in the public company sphere. He has 18 years of experience as an auditor and advisor at the auditing global firm Grant Thornton, where he has had extensive interaction with Realheart as the company’s auditor during year 2019-2022 and is therefore well-informed about the company’s financials and operations.

Jimmy Nybom will join the company on September 6, succeeding the company’s current interim CFO Andreas Hultdin.

“While the process of recruiting a permanent CFO is progressing according to plan, our interim CFO Andreas Hultdin will be handing over the baton to Jimmy Nybom. Jimmy, who was part of the advisory team that supported the IPO of Realheart, is an acknowledged professional in auditing and financials. We wish to thank Andreas for his valuable contributions and wish him good luck in his future endeavors,” says Ina Laura Perkins, CEO of Realheart.

About Realheart
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trial models ahead of a first clinical study in patients. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se

For more information, please contact:
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21 
E-mail: inalaura.perkins@realheart.se
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se

Image Attachments
Jimmy Nybom 2024

Attachments
Realheart Appoints New Interim Chief Financial Officer

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.